KTX-951 - CAS 2573298-36-7

KTX-951, a PROTAC designed for IRAK4 degradation (DC 50 =18 nM), exhibits an oral bioavailability (F%) of 22% in a rat model at a dosage of 10 mg/kg. Additionally, KTX-951 demonstrates promising anticancer potential [1].

IRAK, PROTACs

Immunology/Inflammation, NF-κB, PROTAC

2573255

C46H52F2N8O6

850.95

COc1cc2nn(cc2cc1NC(=O)c1cccc(n1)C(C)(F)F)[C@H]1CC[C@H](CN2CCC3(CC(CCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)C3)CC2)CC1

-20°C

Ice Packs

PROTAC